502867827 06/25/2014

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2914424

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
ALKERMES PHARMA IRELAND LIMITED	06/10/2014

RECEIVING PARTY DATA

Name:	MORGAN STANLEY SENIOR FUNDING, INC.
Street Address:	1585 BROADWAY
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10036

PROPERTY NUMBERS Total: 7

Property Type	Number
Patent Number:	8669281
Application Number:	14212745
Application Number:	14180687
Application Number:	61955976
Application Number:	61943699
Application Number:	61950541
PCT Number:	US2014027401

CORRESPONDENCE DATA

Fax Number: (650)838-5109

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-838-3743

Email: JLIK@SHEARMAN.COM
Correspondent Name: BENJAMIN PETERSEN

Address Line 1: 3000 EL CAMINO REAL, 6TH FLOOR

Address Line 2: SHEARMAN & STERLING LLP
Address Line 4: PALO ALTO, CALIFORNIA 94306

ATTORNEY DOCKET NUMBER:	35613/12286
NAME OF SUBMITTER:	BENJAMIN PETERSEN
SIGNATURE:	/BENJAMIN PETERSEN/
DATE SIGNED:	06/25/2014

502867827 PATENT REEL: 033244 FRAME: 0523

Total Attachments: 5

source=0 - Patent Security Agreement (Alkermes Pharma)#page1.tif

source=0 - Patent Security Agreement (Alkermes Pharma)#page2.tif

source=0 - Patent Security Agreement (Alkermes Pharma)#page3.tif

source=0 - Patent Security Agreement (Alkermes Pharma)#page4.tif

source=0 - Patent Security Agreement (Alkermes Pharma)#page5.tif

PATENT REEL: 033244 FRAME: 0524

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of June 10, 2014 ("Patent Security Agreement"), made by ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) whose registered office is at Connaught House, 1 Burlington Road, Dublin 4, Ireland (the "Grantor"), is in favor of MORGAN STANLEY SENIOR FUNDING, INC., as collateral agent (in such capacity, the "Collateral Agent") for the Secured Parties.

WITNESSETH:

WHEREAS, the Grantor is party to a First Lien Guarantee and Collateral Agreement, dated as of September 16, 2011, as amended on September 25, 2012 (the "Guarantee and Collateral Agreement") in favor of the Collateral Agent and MORGAN STANLEY SENIOR FUNDING, INC., as administrative agent (in such capacity, the "Administrative Agent") pursuant to which the Grantor is required to execute and deliver this Patent Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Guarantee and Collateral Agreement);

WHEREAS, pursuant to the terms of the Guarantee and Collateral Agreement, Grantor has created in favor of the Collateral Agent a security interest in the Patent Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Agents and the Lenders to enter into the Credit Agreement and to induce Lenders to make their respective extensions of credit to the Borrower thereunder and to induce the Qualified Counterparties to enter into the Specified Hedge Agreements and provide financial accommodation, Grantor hereby agrees with the Collateral Agent, for the benefit of the Secured Parties, as follows:

Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by Grantor or in which Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the "Patent Collateral"), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

- (a) all patents, patent applications, certificates of inventions, industrial designs (whether issued or applied for in the United States or any other country or any political subdivision thereof), including, without limitation, each issued patent and patent application identified on Schedule I attached hereto, together with any and all (i) inventions and improvements described and claimed therein, (ii) reissues, divisions, continuations, extensions and continuations-in-part thereof and amendments thereto, (iii) income, fees, royalties, damages, and payments now and hereafter due and/or payable under or with respect to any of the foregoing, including, without limitation, damages, claims and payments for past, present and future infringements, misappropriations and other violations thereof, (iv) rights and remedies to sue for past, present and future infringements, misappropriations and other violations of any of the foregoing and (v) rights, priorities, and privileges corresponding to any of the foregoing throughout the world ("Patents") of such Grantor, including, without limitation, the registered and applied for Patents of such Grantor listed on Schedule I attached hereto; and
- (b) all Proceeds of any of the foregoing;

provided, that (i) this Patent Security Agreement shall not constitute a grant of a security interest in any property to the extent that and for as long as such grant of a security interest would be prohibited by the terms of the Guarantee and Collateral Agreement; and (ii) the security interest granted hereby (A) shall attach at all times to all proceeds of such property, (B) shall attach to such property immediately and

PATENT REEL: 033244 FRAME: 0525 automatically (without need for any further grant or act) at such time as the condition described in <u>clause</u> (i) ceases to exist and (C) to the extent severable, shall, in any event, attach to all rights in respect of such property that are not subject to the applicable condition described in <u>clause</u> (i).

The security interest granted pursuant to this Patent Security Agreement is granted concurrently and in conjunction with security interest granted to the Collateral Agent pursuant to the Guarantee and Collateral Agreement and Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Guarantee and Collateral Agreement. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Guarantee and Collateral Agreement, the provisions of the Guarantee and Collateral Agreement shall govern.

The term of this Patent Security Agreement shall be co-terminus with the Guarantee and Collateral Agreement.

Grantor hereby authorizes and requests that (i) with respect to the Intellectual Property listed on <u>Part-I</u> of <u>Schedule 1</u>, the Commissioner of Patents and Trademarks and (ii) with respect to the Intellectual Property listed on <u>Part-II</u> of <u>Schedule 1</u>, the appropriate filing office in the Republic of Ireland record this Patent Security Agreement.

THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

This Patent Security Agreement may be executed by one or more of the parties to this Patent Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof. A set of the copies of this Patent Security Agreement signed by all the parties shall be lodged with the Borrower, the Administrative Agent and the Collateral Agent.

[Remainder of This Page Intentionally Left Blank.]

IN WITNESS WHEREOF, each Grantor has caused this PATENT SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

GIVEN under the common seal of ALKERMES PHARMA IRELAND LIMITED and delivered as a deed;

Director

Dissections ("Assistant)

Accepted and Agreed:

MORGAN STANLEY SENIOR FUNDING.

INC., as Collateral Agent

Ву.

Name: PP/4820 Title:

3

PATENTS Part-I

Case Number: ALT-012 invention Title: Produts of Fumarates and Their Use in Treating Various Diseases Division: Alkermes Pharma Ireland Ltd.	if Fumarates an a treland Ltd.	d Their Use in	Treating Various Disease	şş				
Country United States of America	Sub Case	Sub Case Case Type ORD	Status Granfed	Application Number 14/032,736	Filing Date 20-Sep-2013	Patent Number 8,669,281	Issue Date 11-Mar-2014	Expiration Date 20-Sep-2033
Status Change: Newly Issued	реп							
Case Number: ALT-012 Invention Title: Produgs of Fumarates and Their Use in Treating Various Diseases Division: Alkermes Pharma Ireland Ltd.	f Fumarates an I freland Ltd.	d Their Use in	Treating Various Disease	\$3				
Country Patent Cooperation Treaty United States of America United States of America	Sub Case A DV	Sub Case Case Type ORD A ORD DV ORD	Status Pending Pending Pending	Application Number PCT/US2014/027401 14/212,745 14/180,687	Filing Date 14-Mar-2014 14-Mar-2014 14-Feb-2014	Patent Number	issue Date	Expiration Date
Status Change: Newly Filed	70 3							
Case Number: ALT-914 Invention Title: Ariphrazole Formulations Having Increased Injection Speeds Division: Alkermes Pharma Ireland Ltd.	Formulations ! ireland Ltd.	Having Increas	sed Injection Speeds					
Country United States of America	Sub Case	Sub Case Case Type 1 PRO	Status Pending	Application Number 61/955,976	Filing Date 20-Mar-2014	Patent Number	Issue Date	Expiration Date 20-Mar-2015
Status Change: Newly Filed	* 53							

PATENT REEL: 033244 FRAME: 0528

Case Number: At T-015 Invention Title: Sufformed and Sulfanamide Prodrugs of Division: Alkermes Pharma freland Ltd.	and Sultanan Ireland Ltd.	nide Prodnugs	of Fumarates and Their U	Fumarates and Their Use in Treating Various Diseases	ses			
Country United States of America	Sub Case	Sub Case Case Type	Status Pending	Application Number 61/943,699	Filing Date 24-Feb-2014	Patent Number	issue Date	Expiration Date 24-Feb-2015
Status Change: Newly Filed	-		·					
Case Number: ALT-016 Invention Thie: Combination Therapies Comprising Furnarates and Prodrugs Thereof <u>Division</u> : Alkennes Pharma Ireland Ltd.	Therapies Correland Ltd.	omprising Fum	arates and Prodrugs Ther	eoí				
Country United States of America	Sub Case	Sub Case Case Type 1 PRO	Status Pending	Application Number 61/950,541	Filing Date 10-Mar-2014	Patent Number	Issue Dete	Expiration Date 10-Mar-2015
Status Change: Newly Filed								

PATENT

REEL: 033244 FRAME: 0529 RECORDED: 06/25/2014